XML 42 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Segment Information (Tables) | 12 Months Ended
--- | ---
Oct. 31, 2020
Segment Reporting [Abstract] |
Schedule of Segment Information | The following represents selected financial information for our segments for the years ended October 31, 2020 and 2019:
|  | Year Ended October 31, |
|  | 2020 |  |  | 2019 |
Net loss: |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | (2,241,443 | ) |  | $ | (5,074,868 | )
Cancer Vaccines |  |  | (828,136 | ) |  |  | (677,450 | )
Anti-Viral Therapeutics |  |  | (1,168,969 | ) |  |  | - |
Cancer Diagnostics |  |  | (5,836,594 | ) |  |  | (5,196,471 | )
Patent Licensing |  |  | (17,221 | ) |  |  | (869,863 | )
Total |  | $ | (10,092,363 | ) |  | $ | (11,818,652 | )
Total operating costs and expenses |  | $ | 9,978,202 |  |  | $ | 12,140,005 |
Less non-cash share-based compensation |  |  | (4,137,460 | ) |  |  | (5,713,746 | )
Operating costs and expenses excluding non-cash share-based compensation |  | $ | 5,840,742 |  |  | $ | 6,426,259 |
Operating costs and expenses excluding non-cash share based compensation: |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | 1,141,542 |  |  | $ | 2,212,090 |
Cancer Vaccines |  |  | 365,681 |  |  |  | 458,392 |
Anti-Viral Therapeutics |  |  | 739,140 |  |  |  | - |
Cancer Diagnostics |  |  | 3,581,377 |  |  |  | 2,689,761 |
Patent Licensing |  |  | 13,002 |  |  |  | 1,066,016 |
Total |  | $ | 5,840,742 |  |  | $ | 6,426,259 |
|  | October 31, |
|  | 2020 |  |  | 2019 |
Total assets: |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | 2,988,124 |  |  | $ | 2,382,460 |
Cancer Vaccines |  |  | 946,923 |  |  |  | 489,881 |
Anti-Viral Therapeutics |  |  | 2,464,361 |  |  |  | - |
Cancer Diagnostics |  |  | 2,869,529 |  |  |  | 2,921,784 |
Patent Licensing |  |  | 184,027 |  |  |  | 499,568 |
Total |  | $ | 9,452,964 |  |  | $ | 6,293,693 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration